The SUMMIT trial, a randomized, placebo-controlled, double-blind phase 3 trial (NCT04847557), 3 was conducted to assess 2 outcomes: the influence of CKD on the clinical responses to tirzepatidea glucagon-like peptide 1 agonist that targets 2 receptors to shrink fat cells and reduce the impacts that enlarged fat cells have on heart and kidney healthrelated to patients with obesity-related HFpEF
At Noom Med, we carefully review each patients medical history and current medications to lessen the risk of interactions and ensure safe treatment
Fibrosing ILDs encompass a group of rare, complex and heterogeneous respiratory disorders that can be linked to many causes, including growth abnormalities or autoimmune conditions like rheumatoid arthritis
Growth hormone is naturally produced by the pituitary gland and is necessary for growth
For our patients considering Ozempic for weight loss , its important to understand the role of body mass index (BMI) in this decision